Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN046 in Advanced Thymic Carcinoma
NCT04469725Phase 2Terminated
- Sponsor
- Alphamab Oncology
- Start
- Dec 2020
- Primary completion
- Jul 2023
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of erfonrilimab in thymic carcinoma (TC), sponsored by Alphamab Oncology. Started Dec 2020; status: terminated.
02
Drugs
erfonrilimab
03
Conditions
thymic carcinoma (TC)
Beyond the preview
Go deeper on NCT04469725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04469725.